Teva's Ajovy has been battling against intense competition in the CGRP migraine prevention field at a disadvantage: It's delivered by syringe, and its rivals use simpler, less intimidating autoinjectors. Until now. But can its own device approval drive a 25% market share grab as execs hope?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,